Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib

PURPOSE: To investigate the feasibility of nintedanib, a novel triple angiokinase inhibitor, for inhibiting lymphatic endothelial cell (LEC)-induced lymphangiogenesis in vitro and inflammatory corneal lymphangiogenesis in vivo. MATERIALS AND METHODS: Methylthiazolyldiphenyl-tetrazolium bromide (MTT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Tong, Gong, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391212/
https://www.ncbi.nlm.nih.gov/pubmed/28435226
http://dx.doi.org/10.2147/DDDT.S130297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391212/
https://www.ncbi.nlm.nih.gov/pubmed/28435226
http://dx.doi.org/10.2147/DDDT.S130297

Ejemplares similares